Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,
Go back to Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 150.91 +1.41 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.50 | 52 Week High | $58.46 | |||
| Open | $151.14 | 52 Week Low | $31.25 | |||
| Day High | $151.83 | P/E | N/A | |||
| Day Low | $150.00 | EPS | $-0.69 | |||
| Volume | 109,677 | |||||
